Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas

NCT01721577 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Investigator went to another institution.

Conditions

Glioblastoma
Gliosarcoma
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Oligoastrocytoma
Anaplastic Ependymoma

Interventions

DRUG: AXL1717

Sponsor

Rush University Medical Center

Collaborators

[object Object]